PMA 204Alternative Names: PMA-204
Latest Information Update: 18 Jul 2016
At a glance
- Originator Pharmedartis
- Class Antineoplastics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer; Prostate cancer; Solid tumours
Most Recent Events
- 18 Jul 2016 PMA 204 is still in preclinical development for Pancreatic cancer, Prostate cancer and Solid tumours in Germany